Idorsia conducts clinical trials globally to advance its studies. Our key assets have the potential to transform treatment in the target indications.
Currently, we support Idorsia activities and clinical studies out of the following locations:
Currently, we support Idorsia activities and clinical studies out of the following locations:
Headquarters of Idorsia Ltd. Responsible for drug discovery, development, registration, production, quality assurance, safety, as well as company management and coordination.
Based in Radnor, Pennsylvania, US – is responsible for the commercial operations in the US.
Based in Tokyo, Japan – performs clinical development and commercial activities on behalf of Idorsia.
A 100% subsidiary of Idorsia Ltd, based in Lörrach, Germany – performs clinical development on behalf of the Group and acts as the Group’s representative for obtaining regulatory approvals in the EU.
A 100% subsidiary of Idorsia Ltd, based in Munich, Germany – is responsible for the Group’s marketing operations in Germany.
A 100% subsidiary of Idorsia Ltd, based in Paris, France – will be responsible for the Group’s marketing operations in France.
A 100% subsidiary of Idorsia Ltd, based in London, United Kingdom – is responsible for the Group’s marketing operations in the United Kingdom.
A 100% subsidiary of Idorsia Ltd, based in Milan, Italy – is responsible for the Group’s marketing operations in Italy.
A 100% subsidiary of Idorsia Ltd, based in Madrid, Spain – is responsible for the Group’s marketing in Spain.
Based in New Jersey, US – performs clinical development on behalf of Idorsia.
Based in Shanghai, PRC – performs research and development on behalf of Idorsia.
Based in Beijing, PRC – performs clinical development on behalf of Idorsia.
A 100% subsidiary of Idorsia Ltd, based in Berlin, Germany – discovers and develops synthetic carbohydrate vaccines to prevent infection.